Abstract
During the past 30 years, remarkable progress has been achieved in understanding the role of the antineutrophil cytoplasmic antibodies (ANCAs) directed against proteinase 3 (PR3) and myeloperoxidase (MPO) in so-called “ANCA-associated vasculitides”. In the right clinical context, ANCAs are a good seromarker for these diseases, have improved nomenclature of systemic vasculitides and have contributed to new pathogenic concepts. However, problems with the clinical applications of ANCA testing in daily practice remain. They can be summarised as follows: assay standardisation and performance; the use of ANCA testing in a clinical setting with a low pretest probability; the relationship between ANCA titres and disease activity remains unclear. The solution to problems regarding the ANCA diagnosis is focussed on the fundamental methods, i.e., correct implementation of IFT and ELISA, the cautious use of commercial assays and restricting the use of the tests to clinical situations with a rather high pretest probability of AAV.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Davies DJ, Moran JE, Niall JF, et al. Segmental necrotizing glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J. 1982;285:606.
Van der Woude FJ, Rasmussen N, Lobatto S. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet. 1985;1:425–9.
Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, Lesavre P, Ludemann J, Rasmussen N, Sinico RA, Wiik A, van der Woude FJ. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int. 1998;53:743–53.
Savige J, Gillis D, Benson E, Davies D, Esnault V, Falk RJ, Hagen EC, Jayne D, Jennette JC, Paspaliaris B, Pollock W, Pusey C, Savage CO, Silvestrini R, van der Woude F, Wieslander J, Wiik A. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol. 1999;111:507–13.
Holle JU, Hellmich B, Backes M, Gross WL, Csernok E. Variations in performance characteristics of commercial enzyme immunoassay kits of the detection of antineutrophil cytoplasmatic antibodies: what is the optimal cut-off? Ann Rheum Dis. 2005;64:1773–9.
Csernok E, Holle J, Hellmich B, Willem J, Tervaert C, Kallenberg CG, Limburg PC, Niles J, Pan G, Specks U, Westman K, Wieslander J, De Groot K, Gross WL. Evaluation of capture ELISA for detection of neutrophil cytoplasmatic antibodies directed against proteinase 3 in Wegener’s granulomatosis: first results from a multicenter study. Rheumatology (Oxford). 2004;43(2):174–80.
Hellmich B, Csernok E, Fredenhagen G, Gross WL. A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3. Clin Exp Rheumatol. 2007;25(44):1–5.
Holle JU, Herrmann K, Gross WL, Csernok E. Comparative analysis of different commercial ELISA systems for detection of anti-neutrophil cytoplasm antibodies in ANCA-associated vasculitides. Clin Exp Rheumatol. 2012;30(1 Suppl 70):S66–9.
Pollock W, Trevisin M, Savige J. Testing on formalin-fixed neutrophils is less sensitive and specific for small vessel vasculitis, and less sensitive for MPO-ANCA, than most ELISAs. J Immunol Methods. 2008;339(82):141–5.
Csernok E, Holle JU. Twenty-years with ANCA: how to test for ANCA –evidence based immunology? Autoimmun Highlights. 2010;1(1):39–45.
Sinclair D, Saas M, Stevens JM. The effect of a symptom related “gating policy” on ANCA requests in routine clinical practice. J Clin Pathol. 2004;57:131–4.
Arnold DF, Timms A, Luqmani R, Misbach SA. Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients. J Clin Pathol. 2010;63(6):678–80.
Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-a meta-analysis. Rheumatology. 2012;51(1):100–9.
Csernok E, Gross WL. Diagnostic significance of ANCA in vasculitis. Nat Clin Pract Rheumatol. 2006;2(4):174–5.
Conflict of interest
The author declares no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Csernok, E. ANCA testing: the current stage and perspectives. Clin Exp Nephrol 17, 615–618 (2013). https://doi.org/10.1007/s10157-012-0735-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-012-0735-y